BioPharm America™ 2012 Program Features Industry’s Biggest Names Providing Insight on Doing Better Deals

BioPharm America™ 2012 Program Features Industry’s Biggest Names Providing Insight on Doing Better Deals

<0> MassBioSarah MacDonald, +1-617-674-5115orEBD GroupErin Righetti, +1-760-930-0500 </0>

The robust program at BioPharm America™ this year will feature executives from big pharma including Alexion Pharmaceuticals, Amgen, AstraZeneca, Bayer HealthCare, Bristol-Myers Squibb, GlaxoSmithKline, Ironwood Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, Shire, and Takeda. The event, organized by EBD Group, the leading partnering firm for the life science industry, will be held September 19–21, 2012 at the Westin Boston Waterfront in Boston, MA, in collaboration with the Massachusetts Biotechnology Council (MassBio).

“With the broad spectrum of biotech and life science companies being represented and the high caliber of attendee, BioPharm America 2012 promises to be the strongest partnering conference we’ve seen to date,” said , President and CEO of MassBio. “There are so many innovative thinkers and industry experts in the Massachusetts supercluster — we are excited to hear what happens when they connect with counterparts from around the globe.”

“This year we absolutely have the best program ever, with provocative topics and some weighty speakers,” said , President of EBD Group. “From the workshop on making your 30-second pitch and the Fierce 15 awards, to the SciBX Innovation Summit, we have some new and engaging offerings that will be a big draw, not to mention the superb partnering opportunities.”

The BioPharm America program kicks off with a big day on Wednesday. Two concurrent workshops will open the morning activities. The first, “Does pharma see value in immunotherapies?” will be moderated by of Maxcyte, with panelists of Coronado Biosciences; of Novartis; of Sangamo BioSciences; and of Celldex Therapeutics.

The other workshop, “Let’s make a deal because ‘Biotech has talent,’” will give audience members 30 seconds to pitch their company, product, technology or service to a star-studded panel of judges. This workshop is moderated by of MacDougall Biomedical Communications, and judges include of BioCentury Publications, Inc.; of Bayer HealthCare; of AstraZeneca; of Novo Nordisk; of Ironwood Pharmaceuticals; of Shire; and of Amgen.

Wednesday’s opening remarks will be followed by a special announcement of the 2012 Fierce 15 with of , followed by a keynote address by of Genzyme, a Sanofi company. Afternoon panels split into a business development and strategy track and a spotlight track.

Thursday’s Keynote panel “From start-up to commercial company and the challenges in between: Could we do it again today?” will be moderated by of BioCentury with speakers of Organogenesis; of Genzyme; of TESARO; and of Alkermes plc.

Friday’s SciBX Innovation in Drug Discovery & Development Summit, held in partnership with Nature Publishing Group and BioCentury Publications Inc. is an exciting addition that will focus on opportunities afforded by macrocycles and constrained peptides in the area of targeting intracellular protein-protein interactions, their potential for improved oral bioavailability and related benefits in advance of a roadmap white paper. Speakers on the SciBX Summitpanel include of Atlas Venture; of Pfizer; of GlaxoSmithKline; of PeptiDream Inc.; of Aileron Therapeutics; and of Harvard Medical School/Third Rock Ventures.

Evening events, networking opportunities, exhibition receptions, company presentations and scheduled partnering meetings are what make BioPharm America the place where biotech industry partnerships get started.

The full BioPharm America 2012 program can be viewed online at

Registration information for BioPharm America can be found by going to

BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.

Additional links and information:

Follow BioPharm America 2012 on Twitter: (hashtag: #BPA12)

MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation’s oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and healthcare, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

EBD Group’s sophisticated web-based partnering service, , is also used as the partnering engine at numerous third-party events around the world, and is the open online community of life science dealmakers that enhances partnering experiences all year long.

Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.

EBD Group has offices in the USA and Europe.

For more information please visit .

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.